### Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Pacira Pha	maceuticals, Inc.							
Form 4								
July 15, 20								
FOR	VI 4 <sub>UNITED</sub>	STATES SE	CURITIES A	ND EXCHANGE	E COMMISSION	OMB A	PPROVAL	
Chaola			Washington,			Number:	3235-0287	
if no lo		STATEMENT OF CHANGES IN BENEFICIAL OW				Expires:	January 31, 2005	
subject Sectior	10		SECUR		WNERSHIL OF	Estimated burden hou	•	
Form 4 Form 5	or				5 1024	response	•	
obligat	ions Section 17			e Securities Excha ling Company Act	nge Act of 1934, t of 1935 or Section	ı		
may co <i>See</i> Ins	ntinue. truction		•	Company Act of 1				
1(b).								
(Print or Type	e Responses)							
	Address of Reporting	g Person <u>*</u> 2.	Issuer Name and	Ticker or Trading	5. Relationship of	Reporting Per	rson(s) to	
Braunstein	n Scott	Syn	nbol		Issuer			
(Last)	(First)		Date of Earliest Tra	iticals, Inc. [PCR≯	(Checl	k all applicabl	e)	
(Last)	(Filst) (		onth/Day/Year)	ansaction	Director 10% Owner			
C/O PACI			/13/2015		X Officer (give below)	title Oth below)	er (specify	
	CEUTICALS, IN WAY, SUITE 30				SVP, Stra	tegy & Corp.	Dev.	
	(Street)		f Amendment, Da		6. Individual or Jo	int/Group Fili	ng(Check	
		File	ed(Month/Day/Year)	)	Applicable Line) _X_ Form filed by C			
PARSIPP	ANY, NJ 07054				Form filed by M Person	ore than One R	eporting	
(City)	(State)	(Zip)	Table I - Non-D	erivative Securities A	Acquired, Disposed of	, or Beneficia	lly Owned	
1.Title of	2. Transaction Date		•••	4. Securities		Ownership	7. Nature of	
Security (Instr. 3)	(Month/Day/Year)	any	Code	Acquired (A) or Disposed of (D)		orm: Direct D) or Indirect	Indirect Beneficial	
		(Month/Day/Ye	ear) (Instr. 8)	(Instr. 3, 4 and 5)	Owned (I Following (I	) nstr. 4)	Ownership (Instr. 4)	
				(A)	Reported		(	
			Code V	or	Transaction(s) (Instr. 3 and 4)			
D . I D		6 1 1	Code V					
Reminder: R	eport on a separate lin	e for each class o	f securities benefi	cially owned directly Persons who res	or indirectly. spond to the collect	tion of S	SEC 1474	
				information con	tained in this form a	are not	(9-02)	
					ond unless the forn ntly valid OMB cont			
	Tab			iired, Disposed of, or options, convertible				
1. Title of	2. 3. Tra	ansaction Date 3	A Deemed	4. 5. Numb	per of 6. Date Exerci	able and	7. Title and Amount of	
Derivative			Execution Date, if				Underlying Securities	

#### Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired or Dispose (D) (Instr. 3, 4 and 5)	(A) ed of	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 67.11	07/13/2015		А	75,000		<u>(1)</u>	07/13/2025	Common Stock	75,000

# **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
Braunstein Scott C/O PACIRA PHARMACEUTICALS, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY, NJ 07054			SVP, Strategy & Corp. Dev.			
Signatures						

#### /s/ Kristen Williams, Attorney-in-Fact

07/15/2015

Date

\*\*Signature of Reporting Person

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to
(1) the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.